The text starts here.

News Release

November 7, 1997

Eisai Announces Completion of US Pharmaceutical Formulation Research and Manufacturing Facility

Tokyo (November 7, 1997) - Eisai Co., Ltd. of Tokyo (President and CEO:Haruo Naito) today announced Eisai Inc., an Eisai US subsidiary, formally launched pharmaceutical formulation research and manufacturing operations with the dedication of 85,000 square-foot facility in Research Triangle Park, North Carolina.

Ground-breaking for the facility took place on May 1, 1996. Located on 52 acres in the Durham County portion of Research Triangle Park, North Carolina, the new facility has begun formulation research and will begin commercial manufacturing operations of ARICEPT(R) (donepezil hydrochloride), a treatment for mild to moderate Alzheimer's disease, in late 1998 and E3810 (code name), a peptic ulcer treatment, which is in Phase III in the US, after receiving FDA clearance.

With the facility's completion, Eisai will have a fully integrated operations system consisting of basic research, clinical development, production and marketing in the US.


Location:   Research Triangle Park, North Carolina
Functions:   Pharmaceutical formulation research and manufacturing
Total Land Area:   52 acres
Total Facility Area:   85,000 square feet
Commercial production:   Late 1998
Construction cost:   approximately $40 million
Employees:   approximately 40 (about 80 expected in late 1998)

Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care systems. The company reported sales of $2.3 billion in 1996 with approximately 14 percent of sales spent for research and development.